PureTech Health Formally Certifies Nasdaq Delisting and Terminates SEC Reporting
Summary
PureTech Health plc has formally filed to terminate its Nasdaq listing and SEC reporting duties, following its previously announced strategic shift to focus on its London Stock Exchange listing.
Key Events · Corporate Governance and Compliance · PRTC
-
Formal Delisting from Nasdaq
The company filed Form 15F-12B to officially terminate its registration of American Depositary Shares (ADSs) under Section 12(g) of the Exchange Act.
-
Termination of SEC Reporting
PureTech Health will cease its duty to file reports under Section 13(a) or 15(d) of the Exchange Act, reducing its US regulatory burden.
-
Primary Trading Market Confirmed
The London Stock Exchange (LSE) is confirmed as the primary trading market, accounting for 93.6% of the company's worldwide trading volume over the past 12 months.
-
Follows Prior Announcement
This filing formalizes the delisting intention previously announced via a Form 6-K on April 29, 2026.
Analysis · PRTC · Life Sciences
This filing formally certifies PureTech Health's previously announced intention to delist its American Depositary Shares from Nasdaq and terminate its reporting obligations with the SEC. This action reduces the company's regulatory burden and streamlines operations by focusing on its primary listing on the London Stock Exchange. For US investors, this means reduced visibility and liquidity for their holdings.
At the time of this filing, PRTC was trading at $17.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $425.8M. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.